DLA Piper represents Neothetics in initial public offering

DLA Piper advised Neothetics, a clinical-stage speciality pharmaceutical company developing therapeutics for the aesthetic market, in the pricing of its initial public offering (IPO) of 4,650,000 shares of its common stock at a public offering price of $14 (£9) per share.

The San Diego-based DLA Piper team representing Neothetics was led by partners Michael Kagnoff and Larry Nishnick and associates Patrick O’Malley and Lindsey Wyman.

This is the ninth US IPO handled by DLA Piper in 2014. Since 2008, the firm’s capital markets group has represented companies, underwriters and placement agents in more than 240 public offerings (equity and debt) in the US and worldwide, including more than 40 IPOs.